Trials / Completed
CompletedNCT03956524
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
An Open-label, Comparative, Clinical Phase 1 Study to Assess the Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- EuBiologics Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of EuTCV, in comparison to TCV (Typbar-TCV™, Bharat Biotech) and Vi-Polysaccharide vaccine (Typhim Vi®, Sanofi Pasteur) in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EuTCV | Single 0.5 mL dose of TCV of EuBiologics co., Ltd. |
| BIOLOGICAL | Typbar-TCV™ | Single 0.5 mL dose of TCV of Bharat Biotech |
| BIOLOGICAL | Typhim Vi® | Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur |
Timeline
- Start date
- 2019-03-16
- Primary completion
- 2019-08-31
- Completion
- 2019-08-31
- First posted
- 2019-05-20
- Last updated
- 2019-12-09
Locations
1 site across 1 country: Philippines
Source: ClinicalTrials.gov record NCT03956524. Inclusion in this directory is not an endorsement.